Menu
Currency
GWAS Study

Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.

Ellinghaus E, Ellinghaus D, Stuart PE et al.

20953188 PubMed ID
GWAS Study Type
14524 Participants
39 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

EE
Ellinghaus E
ED
Ellinghaus D
SP
Stuart PE
NR
Nair RP
DS
Debrus S
RJ
Raelson JV
BM
Belouchi M
FH
Fournier H
RC
Reinhard C
DJ
Ding J
LY
Li Y
TT
Tejasvi T
GJ
Gudjonsson J
SS
Stoll SW
VJ
Voorhees JJ
LS
Lambert S
WS
Weidinger S
EB
Eberlein B
KM
Kunz M
RP
Rahman P
GD
Gladman DD
GC
Gieger C
WH
Wichmann HE
KT
Karlsen TH
MG
Mayr G
AM
Albrecht M
KD
Kabelitz D
MU
Mrowietz U
AG
Abecasis GR
EJ
Elder JT
SS
Schreiber S
WM
Weichenthal M
FA
Franke A
Chapter II

Abstract

Summary of the research findings

Psoriasis is a multifactorial skin disease characterized by epidermal hyperproliferation and chronic inflammation, the most common form of which is psoriasis vulgaris (PsV). We present a genome-wide association analysis of 2,339,118 SNPs in 472 PsV cases and 1,146 controls from Germany, with follow-up of the 147 most significant SNPs in 2,746 PsV cases and 4,140 controls from three independent replication panels. We identified an association at TRAF3IP2 on 6q21 and genotyped two SNPs at this locus in two additional replication panels (the combined discovery and replication panels consisted of 6,487 cases and 8,037 controls; combined P = 2.36 × 10⁻¹⁰ for rs13210247 and combined P = 1.24 × 10⁻¹⁶ for rs33980500). About 15% of psoriasis cases develop psoriatic arthritis (PsA). A stratified analysis of our datasets including only PsA cases (1,922 cases compared to 8,037 controls, P = 4.57 × 10⁻¹² for rs33980500) suggested that TRAF3IP2 represents a shared susceptibility for PsV and PsA. TRAF3IP2 encodes a protein involved in IL-17 signaling and which interacts with members of the Rel/NF-κB transcription factor family.

472 European ancestry cases, 1,146 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

14524
Total Participants
GWAS
Study Type
Yes
Replicated
2,668, European ancestry cases, 762 French Canadian founder population cases, 2,585 cases, 3,485 European ancestry controls, 994 French Canadian founder population controls, 2,412 controls
Replication Participants
European
Ancestry
U.S., Canada, Germany
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.